- Long-term therapeutic response after encorafenib and binimetinib therapy - case report2023 | First Faculty of Medicine
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management2019 | First Faculty of Medicine
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo2022 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial2018 | First Faculty of Medicine
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)2021 | First Faculty of Medicine
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial2018 | First Faculty of Medicine
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma2020 | First Faculty of Medicine
- Current perspectives on the treatment of BRAF mutated colorectal carcinoma2020 | Publication without faculty affiliation
- Case report of a patient with metastatic melanoma treated with several lines of systemic treatment2021 | First Faculty of Medicine
- Anti-EGFR treatment of colorectal cancer2021 | Publication without faculty affiliation
- Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial2023 | First Faculty of Medicine
- Current view on the treatment of colorectal cancer2021 | Publication without faculty affiliation